Oramed Pharmaceuticals INC Form 4 insider transactions

Avraham Gabay, CFO of Oramed Pharmaceuticals, reports the acquisition of 76,000 shares of common stock through the settlement of performance stock units (PSUs).

Oramed Pharmaceuticals CEO Nadav Kidron acquired 433,500 shares of common stock through restricted stock units, increasing his total holdings to 2,259,598 shares.

Oramed Pharmaceuticals' Chief Financial Officer, Avraham Gabay, acquired 188,000 restricted stock units (RSUs) on January 2, 2025.

Miriam Kidron, Chief Scientific Officer of Oramed Pharmaceuticals, acquired 207,000 shares of common stock on January 2, 2025, increasing her total holdings to 1,000,666 shares.

Oramed Pharmaceuticals' COO & CBO, Joshua Hexter, has acquired 194,500 restricted stock units, which will vest over a three-year period.

Avraham Gabay, CFO of Oramed Pharmaceuticals, reports the acquisition of 30,000 Restricted Stock Units (RSUs) that vest on November 7, 2024.

Oramed Pharmaceuticals CEO Nadav Kidron reports acquiring 45,000 shares of common stock and holding 1,826,098 shares directly, along with 126,000 shares indirectly through a wholly-owned corporation.

Miriam Kidron, Chief Scientific Officer of Oramed Pharmaceuticals, reports the acquisition of 30,000 Restricted Stock Units (RSUs) that vest on November 7, 2024.

Joshua Hexter, COO & CBO of Oramed Pharmaceuticals, reports acquiring 30,000 shares of common stock on November 7, 2024.

Avraham Gabay, CFO of Oramed Pharmaceuticals, was granted 140,040 Restricted Stock Units (RSUs) on June 21, 2024.

Director Yehuda Reznick reported the acquisition of 760 Restricted Stock Units (RSUs) of Oramed Pharmaceuticals, vesting in two installments.

Director Yehuda Reznick reports acquisition of 29,800 Restricted Stock Units (RSUs) in Oramed Pharmaceuticals.